1 / 1

Aurobindo Pharma gets USFDA nod for pain reliever Ibuprofen; launch in Sept

Read more about Aurobindo Pharma gets USFDA nod for pain reliever Ibuprofen; launch in Sept on Business Standard. Quoting Nielsen data, Aurobindo Pharma said the estimated market size of ibuprofen capsules OTC is $164 million for the twelve months ending March 2018

Yamikasawant
Download Presentation

Aurobindo Pharma gets USFDA nod for pain reliever Ibuprofen; launch in Sept

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Aurobindo Pharma gets USFDA nod for pain reliever Ibuprofen; launch in Sept Quoting Nielsen data, Aurobindo Pharma said the estimated market size of ibuprofen capsules OTC is $164 million for the twelve months ending March 2018 Aurobindo Pharma has received final approval from the US health regulator to manufacture and market Ibuprofen capsules, used to relieve pain and reduce fever. The approved product is a generic equivalent of Pfizer's Advil Liqui-Gels Capsules. The product will be launched in September 2018. "The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Ibuprofen capsules OTC, 200 mg," Aurobindo Pharma said in a BSE filing. Also Read : Aurobindo Pharma Ltd Share Price. Quoting Nielsen data, Aurobindo Pharma said the estimated market size of ibuprofen capsules OTC is $164 million for the twelve months ending March 2018. The pharma company said it has now a total of 373 ANDA (Abbreviated New Drug Application) approvals (340 final approvals, including 17 from Aurolife Pharma LLC and 33 tentative approvals) from the USFDA. Stock of Aurobindo Pharma was trading 0.61 per cent higher at Rs 610.25 on BSE.

More Related